In June 2025, Spectral AI Inc. submitted a De Novo submission to the U.S. Food and Drug Administration for its DeepView® System, a non-invasive, predictive medical device and associated software platform designed to assess the healing potential of burn wounds. The submission seeks regulatory review for the DeepView System, which combines multispectral imaging with a proprietary AI algorithm to provide clinicians with early, data-driven assessments of burn wound healing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spectral Ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646157-en) on February 02, 2026, and is solely responsible for the information contained therein.